Results 171 to 180 of about 4,104 (188)
Some of the next articles are maybe not open access.
Journal of the Endocrine Society
J. Bertherat: Consulting Fee; Self; Atterocor, Shire, HRA Pharma Rare Diseases, Novartis Pharmaceuticals, Corcept Therapeutics, Recordati Rare Diseases. Grant Recipient; Self; Novartis Pharmaceuticals, Pfizer, Inc., HRA Pharmaceuticals. S. Cannavò: None.
J. Bertherat +11 more
semanticscholar +1 more source
J. Bertherat: Consulting Fee; Self; Atterocor, Shire, HRA Pharma Rare Diseases, Novartis Pharmaceuticals, Corcept Therapeutics, Recordati Rare Diseases. Grant Recipient; Self; Novartis Pharmaceuticals, Pfizer, Inc., HRA Pharmaceuticals. S. Cannavò: None.
J. Bertherat +11 more
semanticscholar +1 more source
De-escalation treatment with pasireotide for acromegaly: a long-term experience
Endocrine, 2023A. Giampietro +5 more
semanticscholar +1 more source
Current role of pasireotide in the treatment of acromegaly.
Best practice & research. Clinical endocrinology & metabolismS. Bhat, Roberto Salvatori
semanticscholar +1 more source

